10 results on '"Blach S"'
Search Results
2. Assessing the hepatitis C epidemiology in Switzerland: It's not that trivial.
- Author
-
Blach S, Bregenzer A, Bruggmann P, Cerny A, Maeschli B, Müllhaupt B, Negro F, Razavi H, Scheidegger C, and Semela D
- Subjects
- Humans, Switzerland epidemiology, Hepacivirus, Hepatitis C epidemiology
- Published
- 2024
- Full Text
- View/download PDF
3. The current and future burden of hepatitis B in Switzerland: a modelling study.
- Author
-
Negro F, Müllhaupt B, Semela D, Blach S, Bruggmann P, De Gottardi A, Dufour JF, Fraga M, Galante A, Razavi H, Vieira Barbosa J, and Razavi-Shearer D
- Subjects
- Infant, Child, Humans, Switzerland epidemiology, Hepatitis B Surface Antigens therapeutic use, Hepatitis B virus, Liver Cirrhosis epidemiology, Prevalence, Carcinoma, Hepatocellular epidemiology, Hepatitis B epidemiology, Hepatitis B complications, Hepatitis B prevention & control, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic epidemiology, Hepatitis B, Chronic prevention & control, Liver Neoplasms epidemiology
- Abstract
Background and Aims: Chronic hepatitis B infection (defined as sustained detection of hepatitis B virus [HBV] surface antigen [HBsAg] protein in serum) is a leading cause of cirrhosis, hepatocellular carcinoma and liver-related deaths. A situation analysis carried out by the Swiss Federal Office of Public Health estimated the HBsAg prevalence in Switzerland to be 0.53% (95% CI: 0.32-0.89%) in 2015 (~44,000 cases). A lower prevalence of chronic HBV in the younger generation and the adoption of universal coverage in the first year of life are expected to decrease the burden of HBV; however, a number of people in key populations (including migrants) remain undiagnosed and untreated, and infected individuals remain at risk of progressing to cirrhosis, hepatocellular carcinoma and death. Our primary objective was to examine the current and estimate the future disease burden of HBV in Switzerland and the impact of migration. The secondary objective was to estimate the impact of changing future treatment numbers., Methods: A modelling study was performed using an existing, validated model (PRoGReSs Model) applied to the Swiss context. Model inputs were selected through a literature search and expert consensus. Population data from the Federal Statistical Office were used alongside prevalence data from the Polaris Observatory to estimate the number of HBV infections among people born abroad. The PRoGReSs Model was populated with and calibrated to the available data and what-if scenarios were developed to explore the impact of intervention on the future burden of disease. A Monte Carlo simulation was used to estimate 95% uncertainty intervals (95% UIs)., Results: In 2020, there were an estimated 50,100 (95% UI: 47,500-55,000) HBsAg+ cases among people born abroad. Among people born in Switzerland, there were approximately 62,700 (UI: 58,900-68,400) total HBV infections (0.72% [UI: 0.68-0.79%] prevalence). Prevalence among infants and children under the age of 5 were both <0.1%. By 2030, prevalence of HBV is expected to decrease, although morbidity and mortality will increase. Increasing diagnosis (90%) and treatment (80% of those eligible) to meet the global health sector strategy on viral hepatitis programme targets could prevent 120 cases of hepatocellular carcinoma and 120 liver-related deaths., Conclusions: Thanks to the historical vaccination programmes and the continued rollout of universal 3-dose coverage in the first year of life, Switzerland is expected to exceed the global health sector strategy targets for the reduction of incidence. While overall prevalence is decreasing, the current diagnosis and treatment levels remain below global health sector strategy targets.
- Published
- 2023
- Full Text
- View/download PDF
4. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
- Author
-
Schorr O, Blach S, Thurnheer C, Ruis C, and Dufour JF
- Subjects
- Antiviral Agents therapeutic use, Goals, Hepacivirus, Humans, Switzerland epidemiology, COVID-19 epidemiology, Hepatitis A, Hepatitis C epidemiology, Hepatitis C, Chronic drug therapy, Liver Neoplasms
- Abstract
Aims of the Study: Since 2014, the Swiss Hepatitis Strategy (SHS) has targeted the elimination of Hepatitis C Virus (HCV) in Switzerland. The epidemiology of HCV is diverse across Swiss cantons, therefore cantonal-level screening and treatment strategies should be developed. This study aimed to identify scenarios to achieve HCV elimination in the canton of Bern by 2030., Methods: A preexisting Markov disease burden model was populated with data for Bern, and used to forecast the current and future prevalence of HCV, annual liver-related deaths (LRDs), and incidence of hepatocellular carcinoma and decompensated cirrhosis until 2030. Scenarios were developed to assess the current standard of care and potential long-term impact of the COVID-19 crisis on the HCV infected population. Additionally, potential scenarios for achieving the WHO 2030 targets and the SHS 2025 and 2030 targets (reduction of new cases of HCV, HCV-related mortality and viremic HCV cases) were identified., Results: In 2019, there were an estimated 4,600 (95% UI: 3,330-4,940) viremic infections in the canton of Bern and 57% (n = 2,600) of viremic cases were diagnosed. This modelling forecasted a 10% increase in LRDs (28 in 2020 to 31 in 2030) with the current standard of care and a 50% increase in LRDs in a scenario assuming long-term delays. To achieve the WHO and SHS targets, the canton of Bern needs to increase the annual number of patients diagnosed (from 90 in 2019 to 250 per year in 2022-2024 [WHO], or 500 per year in 2022-2025 [SHS]) and treated (from 130 in 2019 to 340 per year in 2022-2024 [WHO] or 670 per year in 2022-2025 [SHS])., Conclusions: The SHS goals and the WHO targets for HCV elimination can be achieved in the Swiss canton of Bern by 2030; however, not at the current pace of screening, linkage to care and treatment., Competing Interests: Olivier Schorr was a Master in Public Health university student at the time this work was completed and an employee of Gilead Sciences; This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2022
- Full Text
- View/download PDF
5. HCV disease burden and population segments in Switzerland.
- Author
-
Bihl F, Bruggmann P, Castro Batänjer E, Dufour JF, Lavanchy D, Müllhaupt B, Negro F, Razavi H, Scheidegger C, Semela D, Semmo N, and Blach S
- Subjects
- Adult, Antiviral Agents therapeutic use, Cost of Illness, Humans, Switzerland epidemiology, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C drug therapy, Hepatitis C epidemiology
- Abstract
Background: Switzerland has made strides towards hepatitis C virus elimination, but as of 2019, elimination was not guaranteed. However, political interest in viral hepatitis has been increasing. We sought to develop a better understanding of Switzerland's progress towards HCV elimination and the profile of remaining HCV-RNA-positive patients., Methods: A previously described Markov model was updated with recent diagnosis and treatment data and run to generate new forecasts for HCV disease burden. Two scenarios were developed to evaluate HCV morbidity and mortality under the status quo and a scenario that achieves the Swiss Hepatitis Strategy Elimination targets. Next, an analysis was conducted to identify population segments bearing a high burden of disease, where future elimination efforts could be directed., Results: At the beginning of 2020, an estimated 32 100 viremic infections remained in Switzerland (0.37% viremic prevalence). Adult (≥18 years of age) permanent residents born abroad represented the largest subpopulation, accounting for 56% of HCV infections. Thirteen countries accounted for ≥60% of viremic infections amongst permanent residents born abroad, with most people currently residing in Zurich, Vaud, Geneva, Bern, Aargau and Ticino. Amongst Swiss-born HCV-RNA-positive persons, two-thirds had a history of IDU, corresponding to 33% of total infections., Conclusions: In Switzerland, extra efforts for diagnosis and linkage to care are warranted in foreign-born populations and people with a history of drug use. Population-level measures (eg increasing the number of providers, increase screening) can identify patients who may have otherwise fallen through the gaps or avoided care because of stigma., (© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
6. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
- Author
-
Blach S, Schaetti C, Bruggmann P, Negro F, and Razavi H
- Subjects
- Adolescent, Adult, Female, Hepacivirus isolation & purification, Humans, Male, Mass Screening, Middle Aged, Models, Economic, Quality-Adjusted Life Years, Switzerland, Antiviral Agents economics, Antiviral Agents therapeutic use, Cost-Benefit Analysis, Health Care Costs, Hepatitis C, Chronic drug therapy
- Abstract
Background and Aims: A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years., Methods: A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the economic impact of each scenario. Additionally, we generated a net-zero cost scenario (Scenario 2), assuming the same treatment paradigm as Scenario 1 but at the treatment price that would break even by 2031., Results: In the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031. Cumulative direct costs are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031. In Scenario 1, annual direct costs first increased to 175 million CHF by 2018, before declining to 44 million CHF by 2031. Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031. For Scenario 2, the treatment price needed to achieve break-even by 2031 considering only direct costs would be 27,900 CHF per patient. By 2031, Scenarios 1 and 2 would gain 58,300 QALYs. In both scenarios, the ICER drops below the cost-effectiveness threshold of 78,000 CHF in 2018. Over the 15-year span, the ICER was determined to be 2,200 CHF for Scenario 1., Conclusions: Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared to the historical base case and could achieve break-even by 2031 at a price of 27,900 CHF.
- Published
- 2019
- Full Text
- View/download PDF
7. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
- Author
-
Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Müllhaupt B, Negro F, and Semela D
- Subjects
- Carcinoma, Hepatocellular mortality, Hepacivirus pathogenicity, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic prevention & control, Humans, Liver Neoplasms mortality, Prevalence, Switzerland epidemiology, Viremia, Antiviral Agents therapeutic use, Disease Eradication methods, Hepatitis C, Chronic epidemiology, Organizational Objectives
- Abstract
Background and Aims: Direct-acting antiviral agents have revolutionised hepatitis C treatment. In 2014, the Swiss Hepatitis Strategy was developed to eliminate hepatitis C virus (HCV) infection and the associated liver-related morbidity and mortality by 2030. Though numerous national studies and assessments have identified a relatively low prevalence rate of 0.7% in the country, little has been done to identify the epidemiology of HCV on the regional, or micro, level. This study aimed to identify scenarios to achieve the objectives of Swiss Hepatitis Strategy by 2030 in eastern, western and northern regions in Switzerland., Methods: Three Excel-based Markov disease burden models, based on hospital- and region-specific data, were developed to forecast the current and future prevalence of HCV infection by fibrosis stage and liver disease stage to 2030. Two scenarios were developed to evaluate the disease burden in St Gallen, Geneva and Zurich: a Base 2016 scenario, representing the current standard of care in each canton, and a second, potential scenario to achieve the Swiss Hepatitis Strategy goals., Results: In 2015, the estimated viraemic prevalence in St Gallen was 0.5% (0.5–0.6%) corresponding to 2800 (2600–3100) cases. In Geneva and Zurich, the estimated prevalence was slightly higher, with an estimated 0.7% (0.6–0.7%) viraemic prevalence, or 3300 (3000–3600) cases in Geneva and 0.7% (0.7–0.8%) viremic prevalence, or 10,800 (9900–11,900) infectionsin Zurich. In order to achieve the Swiss Hepatitis Strategy goals of a 30% reduction in new infections, total viraemic infections, liver transplants, and hepatocellular carcinoma cases by 2020 and a 90% reduction by 2030, all regions will need to increase the annual number of treated and diagnosed patients up to 2030. In St Gallen, an up-front investment to treat 430 patients annually by 2020 would be necessary, to achieve the 2020 goals. After 2020, treatment could be reduced to ~150 patients annually until 2030. The number of patients diagnosed, however, would need to be sustained at 130 annually after 2020. In Geneva, 235 patients need to be treated, with 140 diagnosed annually between 2019 and 2030 to achieve both 2020 and 2030 goals. In Zurich, 850 patients will need to be treated annually in 2019 and 2020 and the number of diagnosed will need to expand to 350 individuals annually by 2022., Conclusions: Intensified screening for chronic hepatitis C and increased access to direct-acting antivirals are necessary to meet the Swiss hepatitis strategy elimination goals over the next 12 years.
- Published
- 2019
- Full Text
- View/download PDF
8. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
- Author
-
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, and Negro F
- Subjects
- Cost of Illness, Disease Progression, Hepatitis C prevention & control, Hepatitis C virology, Humans, Liver Cirrhosis prevention & control, Liver Cirrhosis virology, Switzerland epidemiology, Disease Eradication, Hepacivirus pathogenicity, Hepatitis C epidemiology, Liver Cirrhosis epidemiology
- Abstract
Catalyzed by the concerns over the growing public health and economic burden of Hepatitis C virus (HCV) in Switzerland, a diverse group of experts and patient representatives came together in 2014 to develop the Swiss Hepatitis Strategy, setting targets for the elimination of viral hepatitis in Switzerland by 2030. Previous studies have reported the estimated number of chronic HCV infections and forecasted burden of disease given different intervention strategies. However, given new prevalence data by the Swiss Federal Office of Public Health, which decreased total infections by about half, an updated analysis is warranted. We aimed to provide an updated viremic prevalence estimate for Switzerland and evaluate the impact on forecasted liver related morbidity and mortality of an 'inaction' scenario and intervention scenarios to achieve the Global Health Sector Strategy for Viral Hepatitis and Swiss Hepatitis Strategy goals by 2030. A Markov disease-progression model was used to calculate the present and future burden of HCV infection by disease stage according to these different strategies. In 2017, there were an estimated 36,800 (95% UI: 26,900-39,200) viremic infections in Switzerland. Given the current standard of care, total viremic infections are expected to decline by 45%, while cases of decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths will decrease by 20%. If treatment and diagnosis efforts were to cease in 2018, late stage HCV-related morbidity and mortality would increase by 90-100% by 2030. Increasing treatment and diagnosis to achieve the Global Health Sector Strategy or Swiss Hepatitis Strategy goals by 2030, will reduce the number of chronic infections to less than 13,000 and 4,000, respectively. Although the HCV epidemic is declining in Switzerland, efforts to expand diagnosis and treatment are needed to achieve elimination by 2030., Competing Interests: This work was supported by Gilead Sciences. Gilead Sciences had no input on the content, the study design, data selection, decision to publish or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. As the corresponding author, I declare, on behalf of all my co-authors that there no additional competing interests.
- Published
- 2018
- Full Text
- View/download PDF
9. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
- Author
-
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, Razavi H, and Semela D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cohort Studies, Cost-Benefit Analysis, Hepacivirus, Humans, Infant, Infant, Newborn, Mass Screening, Middle Aged, Quality-Adjusted Life Years, Switzerland epidemiology, Young Adult, Hepatitis C diagnosis, Hepatitis C epidemiology, Viremia diagnosis, Viremia epidemiology
- Abstract
Objective: In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies., Study Design: Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and government reports. A disease progression model was used to age the infected population to 2015. The HCV distribution was then used to identify 5-year age cohorts with the highest HCV prevalence. The estimated number of cases needed to screen within an age cohort was calculated using the estimated viraemic prevalence, removing the percent previously diagnosed., Results: In 2015, the median age of the viraemic HCV infected population was 49 years, with 75% of the population born between 1951 and 1985. Random screening of the general population could identify one new viraemic HCV case per 159 persons screened, compared with targeted birth cohort screening, which could identify one new viraemic HCV case per 90-99 persons screened., Conclusion: Considering only the direct cost of screening and treatment informing tests, targeted screening by birth cohort is more effective and cost effective than random screening in the general population.
- Published
- 2015
- Full Text
- View/download PDF
10. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
- Author
-
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, and Negro F
- Subjects
- Adolescent, Adult, Female, Hepacivirus pathogenicity, Hepatitis C, Chronic economics, Hepatitis C, Chronic therapy, Humans, Liver Cirrhosis economics, Liver Cirrhosis therapy, Liver Transplantation, Male, Middle Aged, Switzerland, Antiviral Agents therapeutic use, Hepatitis C, Chronic epidemiology, Liver Cirrhosis epidemiology
- Abstract
Background: Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortality. Furthermore, the costs associated with untreated HCV were modeled., Methods: Hepatitis C disease progression and mortality were modeled. Baseline historical assumptions were collected from the literature and expert interviews and strategies were developed to show the impact of different levels of intervention (improved drug cure rates, treatment and diagnosis) until 2030., Results: Under the historical standard of care, the number of advanced stage cases was projected to increase until 2030, at which point the annual economic burden of untreated viremic infections was projected to reach €96.8 (95% Uncertainty Interval: €36 - €232) million. Scenarios to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190 ≥F2 or 3,200 ≥F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75% and 57%, respectively., Conclusions: With today's treatment efficacy and uptake rates, hepatitis C disease burden is expected to increase through 2030. A substantial reduction in disease burden can be achieved by means of both higher efficacy drugs and increased treatment uptake. However, these efforts cannot be undertaken without a simultaneous effort to diagnose more infections.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.